Endogenous interference in imunoassays in clinical chemistry. A rewiev

Weber, T.; Käpyaho, Kirsti; Tanner, Pirjo

doi:10.3109/00365519009085803

Cited by 57 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequently described interfering mechanisms are those caused by heterophilic antibodies, human anti-mouse antibodies, rheumatoid factors, and complement [reviewed in Refs. (19,20 )]. Introduction of blocking agents (e.g., mouse serum or IgG) is often useful in eliminating this type of interference (21,22 ).…”

mentioning

confidence: 99%

Negative Interference in Cardiac Troponin I Immunoassays from a Frequently Occurring Serum and Plasma Component

et al. 2003

View full text Add to dashboard Cite

Background: Cardiac troponin I (cTnI) is a sensitive marker of cardiac injury, but cTnI assays, like other immunoassays, are susceptible to interferences. We evaluated the presence of interfering substances by measuring the recovery of cTnI added to samples from volunteers and from patients with acute coronary syndromes (ACS). Methods: We added a ternary complex of human cardiac troponin (30 -500 g/L) or cTnI from serum to samples from healthy volunteers and ACS patients. We measured cTnI with a two-site sandwich time-resolved immunofluorometric assay using two antibodies against epitopes in the central stable part of cTnI. We also analyzed 108 heparin-plasma samples from 16 ACS patients with this assay, with an assay based on four antibodies, and with two commercial cTnI assays, Ax-SYM and ACS:180. Results: In samples from both healthy persons and ACS patients, recoveries for our assay were 1-167% (range). Recoveries were increased by addition of an antibody with an epitope in the N-terminal region of cTnI to the solid phase and an antibody with an epitope in the C-terminal region as a second detection antibody. In 2 of 16 patients with ACS, normal cTnI concentrations found when measured with the original assay demonstrated clinically abnormal (up to 10-fold higher) results with the additional N-and C-terminal antibodies in the early phase of infarction. Both commercial cTnI assays also

show abstract

mentioning

confidence: 99%

Negative Interference in Cardiac Troponin I Immunoassays from a Frequently Occurring Serum and Plasma Component

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Blood collection tubes are not inert containers but have several constituents, including substances in and/or applied to rubber stoppers, tube wall material, surfactants, anticoagulants, separator gels and clot activators that can potentially interfere with immunoassays (Weber, 1990). Many laboratories have converted from glass to plastic collection tubes for convenience.…”

Section: Blood Collectionmentioning

confidence: 99%

“…Albumin may interfere as a result of its high concentration and its ability to bind or release large proportions of ligand. Complement binds to the Fc fragment of immunoglobulins and can block the analyte-specific binding sites of antibodies (Weber et al, 1990). Lysozyme can form a bridge between the solid-phase IgG and the detector antibody (Selby, 1999).…”

Section: Other Proteinsmentioning

confidence: 99%

Interferences in Immunoassays

Sztefko

2012

Advances in Immunoassay Technology

View full text Add to dashboard Cite

“…

Immunoassay interferences are diverse in scope (1)(2)(3)(4)(5)(6)(7)(8) and are the subject of several recent large-scale studies (9, 10 ), opinions, and editorials (6,11 ). Most interferences originate from components of the sample (e.g., human anti

…”

mentioning

confidence: 99%